EQL Pharma AB (publ)

NGM:EQL 주식 보고서

시가총액: SEK 1.6b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

EQL Pharma 관리

관리 기준 확인 1/4

EQL Pharma's CEO는 Axel Schorling, Aug2022 에 임명되었습니다 의 임기는 1.83 년입니다. 는 SEK 15.61M 가치에 해당하는 회사 주식의 1.07% 직접 소유합니다. 15.61M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 5.1 년입니다.

주요 정보

Axel Schorling

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기1.8yrs
CEO 소유권1.1%
경영진 평균 재임 기간1.8yrs
이사회 평균 재임 기간5.1yrs

최근 관리 업데이트

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Recent updates

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

CEO

Axel Schorling (38 yo)

1.8yrs

테뉴어

Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...

리더십 팀

이름위치테뉴어보상소유권
Christer Fahraeus
Founder & Chairman18.4yrsSEK 1.50m데이터 없음
Axel Schorling
President & CEO1.8yrs데이터 없음1.07%
SEK 17.4m
Anna Jonsson
Chief Financial Officer2.5yrs데이터 없음0.047%
SEK 768.9k
Martin Kristofferson
Chief Operating Officer1.8yrs데이터 없음0.052%
SEK 851.2k
Alexander Brising
Chief Commercial Officerno data데이터 없음0.88%
SEK 14.4m
Carl Lindgren
Chief Business Development Officer1.3yrs데이터 없음데이터 없음

1.8yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: EQL 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름위치테뉴어보상소유권
Christer Fahraeus
Founder & Chairman18.4yrsSEK 1.50m데이터 없음
Rajiv Modi
Non Independent Director9.4yrs데이터 없음데이터 없음
Linda Neckmar
Independent Director4.4yrs데이터 없음0.0086%
SEK 140.0k
Anders Mansson
Independent Director5.8yrs데이터 없음0.034%
SEK 560.0k
Per Svangren
Independent Director3.4yrs데이터 없음0.034%
SEK 560.0k
Per Ollermark
Independent Director3.4yrs데이터 없음데이터 없음

5.1yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: EQL 의 이사회는 경험(평균 재직 기간 5.1 년)으로 간주됩니다.